Medical.watch

Get practice changing insights in oncology/hematology. #MedTwitter

[A.n.n. @fireflyann]

The algorithm is fascinating & extensive. Love the references for all the decision points.

Wish the graphic was a little less blurry as would love to share more widely.

Maybe a spot in graphic for 1st/2nd line trial consult? mountaineer 3, BbopCo all valid options

[Medical.watch @MedwatchHQ]

Top Post of the Week in #RCC:

[Enrique Grande @drenriquegrande]

💉 Personalized mRNA cancer vaccines like intismeran autogene (V940/mRNA-4157) can work in genitourinary cancers?
Three ongoing studies are particularly interesting.
🔵 KIDNEY CANCER — INTerpath-004
This randomized, double-blind Phase II study is evaluating adjuvant:
V940 + pembrolizumab vs placebo + pembrolizumab following nephrectomy in patients with RCC at increased risk of recurrence.
The primary endpoint is disease-free survival, with distant metastasis-free survival and overall survival among the secondary endpoints.
If individualized neoantigen vaccination works in RCC, it could therefore tell us something very important about the biology of this platform: its potential may extend beyond simply selecting tumors with very high mutational burden.
🟠 MUSCLE-INVASIVE BLADDER CANCER — INTerpath-005
Here the development strategy is even more ambitious. INTerpath-005 is a Phase I/II program exploring V940 in two different settings.
One cohort evaluates a perioperative strategy combining:
V940 + pembrolizumab + enfortumab vedotin in cisplatin-ineligible patients undergoing radical cystectomy. Another randomized cohort evaluates adjuvant:
V940 + pembrolizumab vs placebo + pembrolizumab in patients with high-risk resected muscle-invasive urothelial carcinoma.
Could we combine three completely different therapeutic principles?
💥 EV → rapidly kills Nectin-4-expressing tumor cells
🔓 Pembrolizumab → releases PD-1-mediated immune inhibition
🎯 V940 → potentially generates an individualized T-cell response against that patient's unique tumor neoantigens
ADC + checkpoint inhibition + personalized vaccination.
Three mechanisms. One objective: eradicate micrometastatic residual disease before it can become clinically visible.
And there is another bladder cancer study that should not be overlooked.
🟡 NON-MUSCLE-INVASIVE BLADDER CANCER — INTerpath-011
This ongoing randomized Phase II study is evaluating: V940 + BCG vs BCG alone in treatment-naïve high-risk NMIBC.
I find this particularly intriguing. BCG has successfully exploited the immune system against bladder cancer for decades. Combining this established local immunotherapy with a systemic, individualized neoantigen-directed immune strategy represents a completely different way of thinking about treatment intensification in early bladder cancer.
Of course, none of these studies is guaranteed to reproduce what we have seen in melanoma.
For someone who has spent much of his career developing new treatments for kidney and bladder cancer, I find the possibility particularly exciting.
Precision oncology has traditionally meant finding the right drug for the right patient.
Personalized mRNA vaccines introduce an even more ambitious concept:
creating a different drug for each individual patient's cancer.

@OncoAlert @_SEOM @GuardConsortium @urotoday @GUOncologyNow @LACOG_group @GEPAC_

[Simon C @scserendipity1]

One of the best. Hash always kind and supportive to me.

Disagreement is fine. Let’s remain respectful and collegiate

A guiding principle of Open Medicine @OpenMedInsights

[Medical.watch @MedwatchHQ]

Top Post of the Week in #ProstateCancer:

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 Start ADT + ARPI & metabolic dysfunction follows, often in just a few months🚨

@JAMAOnc

👥 16,924 men w/ #ProstateCancer starting ADT + ARPI, no prior metabolic dx

📊 12-mo cumulative incidence:
🔺 New HTN 83%
🔺 Dyslipidemia 52%
🔺 Metabolic syndrome 39%
⏱️ Median time to 1st abnormality: 1 mo. MetS: 2.6 mo

🔗 https://t.co/i5GLEJlUsP

@AmerUrological @PCFnews @PCF_Science @UroOnc @UrologyTimes @urotoday @renalandurology

[Medical.watch @MedwatchHQ]

"Patients and families want to know that the doctor caring for them also cares about them," a terrific discussion with @jillfeldman4 @OncBrothers

👏👏👏

[Medical.watch @MedwatchHQ]

Amazing words from @marklewismd ♥️♥️♥️

[Medical.watch @MedwatchHQ]

For my physician colleagues, a 🧵...

1/ You're not just here to scroll—you're here to teach, connect, & empower. 🩺 Social media is the town square for health conversations. Let’s talk about why your presence matters.👇

[Medical.watch @MedwatchHQ]

Great example of HR+/HER2- mBC treatment algorithm from @SuyogCancer

[Kate Sears @OpenMedKate]

Hi friends, it's #ProstateCancer Friday! Here are Top Posts of the Week 🧵

1/ @DrSpratticus @jeshoag and @SBasourakos on practice patterns in prostate cancer:
https://t.co/SRoDkyvBGx

[KOL Pulse AI @KolPulseAI]

AI in Oncology

👉"Will Autonomous AI Exceed AI-Aided Physicians as the Best Medical Care?" — @ZekeEmanuel and co-authors in JAMA, Aug 17.

👉@dr_yakupergun largely agrees. @RenoHemonc sees a workforce glut coming.

👉@jryckman3 discusses an EviCore denial that cited an AI-hallucinated publication.

Every post verbatim: https://t.co/R6GbhS0O3F

[Paolo Tarantino @PTarantinoMD]

#TBFP is back with a summer edition! 🏝️ @JAMouabbi and I review the most impactful #ASCO26 abstracts, starting from… 👇

[Dr Sarah Sammons @drsarahsam]

Ready to serve the women of Baltimore and communities across Maryland.

I will begin seeing breast cancer patients next week at the University of Maryland Greenebaum Comprehensive Cancer Center, and in September our team will move into the new Roslyn and Leonard Stoler Center for Advanced Medicine, the future home of Greenebaum.

It is a privilege to care for patients and their families during some of life’s most challenging moments. I look forward to serving our community in this remarkable new space.

#BreastCancer #BreastOncology #Baltimore #Maryland #CancerCare @UMBaltimore @UMmedschool

[Medical.watch @MedwatchHQ]

@OncoAdvLukas @JAMA_current @vkhosla Agree 100%

[Medical.watch @MedwatchHQ]

https://t.co/kSI2r9Y3Gu

[Medical.watch @MedwatchHQ]

@VincentRK @PTarantinoMD @TylerSbrt @VivekSubbiah @montypal @DrYukselUrun @ravi_b_parikh @VanAllenLab @jasonwilliamsmd @scserendipity1 @OncBrothers

[Kate Sears @OpenMedKate]

Hi friends, it's #BreastCancer Tuesday! Here are Top Posts of the Week 🧵

1/ @kazuki_nozawa on T-DXd rechallenge in HER2+ metastatic disease (EN-SEMBLE):
https://t.co/h2afEjl6nq